[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2023108905A1 - 肌苷在制备治疗新型冠状病毒肺炎的药物中的应用 - Google Patents

肌苷在制备治疗新型冠状病毒肺炎的药物中的应用 Download PDF

Info

Publication number
WO2023108905A1
WO2023108905A1 PCT/CN2022/078715 CN2022078715W WO2023108905A1 WO 2023108905 A1 WO2023108905 A1 WO 2023108905A1 CN 2022078715 W CN2022078715 W CN 2022078715W WO 2023108905 A1 WO2023108905 A1 WO 2023108905A1
Authority
WO
WIPO (PCT)
Prior art keywords
inosine
cov
sars
novel coronavirus
drug
Prior art date
Application number
PCT/CN2022/078715
Other languages
English (en)
French (fr)
Inventor
高月
周维
陈惠鹏
高玉伟
刘曙晨
孙云波
王宁宁
李恩涛
Original Assignee
中国人民解放军军事科学院军事医学研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国人民解放军军事科学院军事医学研究院 filed Critical 中国人民解放军军事科学院军事医学研究院
Priority to US18/271,296 priority Critical patent/US20240299436A1/en
Publication of WO2023108905A1 publication Critical patent/WO2023108905A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • the invention relates to the field of biomedical technology, in particular to the application of inosine in the preparation of drugs for treating novel coronavirus pneumonia.
  • Inosine is the most common hypoxanthine nucleotide substance, widely exists in related animals and plants, it participates in various physiological functions and metabolic processes of the body, and is an important medicine and raw material for the synthesis of other medicines;
  • inosine can be processed into injections, oral liquids or tablets; inosine has good cell membrane permeability and can directly enter cells to participate in substance metabolism.
  • Clinically, inosine is suitable for various acute and chronic liver diseases, Symptoms such as heart disease, leukopenia or thrombocytopenia, central retinitis, and optic atrophy.
  • Novel coronavirus is a new strain of coronavirus that has never been found in humans. It is an RNA virus with a single-stranded, linear RNA genome. The virus particle is round or oval, and the positive strand RNA means that the virus enters the cell to directly synthesize proteins, and the negative strand is produced by RNA polymerase for self-replication.
  • the new crown pneumonia epidemic has become a global pandemic, which has had a major adverse impact on human health and life. As of now, there have been more than 200 million cumulative confirmed cases worldwide, and it is still spreading rapidly in some countries.
  • the object of the present invention is to provide a kind of application of medicine in the treatment of novel coronavirus pneumonia, described medicine is inosine, and this medicine can reduce the high expression of IL-6 induced by SARS-COV-2, thereby can effectively control SARS-COV-2.
  • Inflammatory damage to the lungs caused by CoV-2 has greatly improved the survival rate of SARS-CoV-2 critical illness.
  • the drug has brought hope to patients with severe and critically ill new coronary pneumonia and their families, and provided new ideas for treating severe and critically ill patients with new coronary pneumonia.
  • the present invention provides the application of inosine in the prevention and/or treatment of novel coronavirus pneumonia.
  • the present invention also provides the use of inosine in the preparation of drugs for preventing and/or treating novel coronavirus pneumonia.
  • the creatinine treats the novel coronavirus pneumonia by inhibiting the secretion of the cytokine IL-6 and/or alleviating the lung inflammatory damage caused by SARS-CoV-2.
  • the treatment of novel coronavirus pneumonia includes improving the survival rate of severe and/or critically ill patients treated for novel coronavirus pneumonia.
  • the dosage form of the creatinine is one or more of tablet, capsule, oral liquid preparation, emulsion and injection.
  • the dosage form of the drug is one or more of tablets, capsules, oral liquid preparations, emulsions and injections.
  • inosine can reduce the level of inflammatory factors in diseases such as autoimmune diseases, cancer or hypersensitivity pneumonitis, and inhibit the activation of macrophages, lymphocytes and neutrophils, thereby improving intestinal and lung injuries. And inosine can be regulated by cytokine storm, thereby improving the survival rate of severe or critical COVID-19.
  • Inosine can alleviate the lung histopathological changes induced by SARS-COV-2 and inhibit the secretion of cytokine IL-6.
  • IL-6 is one of the most critical cytokines, and its severity is closely related to the increase of IL-6. Therefore, controlling IL-6 can help
  • inosine can inhibit the high expression of IL-6 induced by SARS-CoV-2, thereby effectively controlling the lung inflammatory injury caused by SARS-CoV-2, and thus greatly increasing the risk of SARS-CoV-2. critical illness survival rate.
  • the present invention has the following beneficial effects:
  • the inosine drug can reduce the high expression of IL-6 induced by SARS-CoV-2, so as to effectively control the lung inflammatory injury caused by SARS-CoV-2, and thus greatly improve the survival of severe cases of SARS-CoV-2 Rate.
  • the inosine drug brings hope to patients with severe and critically ill patients with new coronary pneumonia and their families, and provides a new idea for the treatment of patients with severe and critically ill patients with new coronary pneumonia.
  • Fig. 1 is the statistical diagram of the experimental data that inosine according to the embodiment of the present invention can improve the survival rate of the new crown lethal animal model
  • Fig. 2 is a statistical diagram of experimental data showing that inosine according to the embodiment of the present invention can promote the weight recovery of animals infected with the new crown;
  • Fig. 3 is a schematic diagram of the experimental results showing that inosine according to the embodiment of the present invention can effectively control and recover the inflammatory injury of the lungs of animals infected with the new crown;
  • Fig. 4 is a schematic diagram of the experimental results showing that inosine can inhibit the level of IL-6 induced by SARS-CoV-2 according to the embodiment of the present invention.
  • Embodiment A kind of application of medicine in the treatment of new coronavirus pneumonia, medicine is inosine, and inosine is applied to suppress IL-6 level, thereby suppresses SARS-COV-2; Inosine is tablet, capsule, oral liquid One or more of formulations, emulsions and injections.
  • Inosine can significantly improve the survival rate of critically ill patients with SARS-CoV-2.
  • the detection result of this embodiment is as follows:
  • Inosine can improve the survival rate of animal models of new crown fatality, and can promote the weight recovery of new crown infected animals.
  • inosine can increase the survival rate of mice.
  • the results of the study showed that the Balb/c mice infected with SARS-COV-2 (model group) died on the 4th to 7th day due to multi-organ inflammation caused by virus infection, and lost significant weight.
  • Inosine group After prophylactic administration of inosine, we observed that the survival period of Balb/c mice was significantly prolonged, the body weight of the mice decreased to a small extent, and the body weight gradually recovered on the 8th day after infection.
  • Inosine can alleviate SARS-COV-2-induced lung histopathological changes in mice.
  • inosine was able to attenuate SARS-COV-2-induced histopathological changes in mouse lungs.
  • the effect of inosine on lung histopathology was observed by H&E staining.
  • the results showed that, compared with the blank control group (Vehicle group), the SARS-COV-2 infection group (model group) could see point and sheet hemorrhage, and a large number of neutral Granulocyte infiltration and pulmonary interstitial edema; while the oral inosine group (Inosine group) had a complete structure of lung tissue, clear alveolar cavities, no congestion in the alveolar wall, and significantly improved inflammatory infiltration compared with the SARS-COV-2 group.
  • Inosine inhibits the secretion of cytokine IL-6.
  • IL-6 is one of the most critical cytokines, and its severity is closely related to the increase of IL-6; in the cytokine storm induced by SARS-CoV-2, IL-6 6 also plays an important role.
  • inosine the level of cytokine IL-6 in mouse serum was measured by Elisa. The results showed that inosine (Inosine group) could inhibit the high expression of IL-6 induced by SARS-COV-2 and help to control the cytokine storm by controlling IL-6.
  • Inosine can effectively control the lung inflammatory injury caused by SARS-CoV-2 by inhibiting the level of IL-6, and greatly improve the survival rate of critically ill patients with SARS-CoV-2.
  • the drug can reduce the high expression of IL-6 induced by SARS-CoV-2, thereby effectively controlling the lung inflammatory damage caused by SARS-CoV-2, thereby greatly increasing the level of SARS-CoV -2 critical illness survival rate.
  • the drug has brought hope to patients with severe and critically ill new coronary pneumonia and their families, and provided new ideas for treating severe and critically ill patients with new coronary pneumonia.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

肌苷在制备治疗新型冠状病毒肺炎的药物中的应用，所述药物的剂型为片剂、胶囊、口服液体制剂、乳液或注射液。肌苷能够抑制SARS-COV-2诱导的IL-6的水平，减轻SARS-COV-2导致的肺部炎性损伤，进而提高SARS-COV-2危重症存活率。

Description

肌苷在制备治疗新型冠状病毒肺炎的药物中的应用
本申请要求于2021年12月16日提交中国专利局、申请号为“202111541575.0”、发明名称为“一种药物在治疗新型冠状病毒肺炎中的应用”的中国专利申请的优先权，其全部内容通过引用结合在本申请中。
技术领域
本发明涉及生物医学技术领域，尤其涉及肌苷在制备治疗新型冠状病毒肺炎的药物中的应用。
背景技术
肌苷(Inosine)属于最常见次黄嘌呤类核苷酸物质，广泛存在有关动植物机体内，它参与机体的各种生理机能及代谢过程，是一种重要的医药和合成其他药物的原料；在医药工业中，肌苷可加工成注射液、口服液或片剂；肌苷具有良好的细胞膜通透性，能直接进入细胞参与物质代谢，临床上肌苷适用于各种急慢性肝脏疾病、心脏病、白血球或血小板减少症、中心视网膜炎和视神经萎缩等症状。
新型冠状病毒(SARS-COV-2)是一种从未在人体内发现的新型冠状病毒株。它是一种RNA病毒，基因组为单链、线性RNA。病毒颗粒呈圆形或椭圆形，正链RNA意味着病毒进入细胞直接合成蛋白质，并通过RNA聚合酶产生负链进行自我复制。新冠肺炎疫情已经成为一场全球性的大流行，对人类健康和生命产生了重大的不利影响，截至目前，全球已有超过两亿例的累计确诊病例，且仍在一些国家快速传播。
感染SARS-COV-2的许多重症和危重患者经常出现免疫系统的过度反应，对危重症患者的存活率存在重大影响，寻找一种对新冠病毒有抑制作用的药物具有重要意义。
发明内容
本发明的目的是提供一种药物在治疗新型冠状病毒肺炎中的应用，所述药物为肌苷，该药物能够降低SARS-COV-2诱导的IL-6的高表达，从而能够有效控制SARS-CoV-2导致的肺部炎性损伤，进而大幅提升SARS-CoV-2危重症存活率。该药物为重症、危重症新冠肺炎患者及其家庭带来了希望，并为治疗新冠肺炎重症、危重症患者提供了新思路。
本发明的上述技术目的是通过以下技术方案得以实现的：
本发明提供了肌苷在预防和/或治疗新型冠状病毒肺炎中的应用。
本发明还提供了肌苷在制备预防和/或治疗新型冠状病毒肺炎的药物中的应用。
优选的，所述肌酐通过抑制细胞因子IL-6的分泌和/或减轻SARS-CoV-2导致的肺部炎性损伤来治疗新型冠状病毒肺炎。
优选的，所述治疗新型冠状病毒肺炎包括提高治疗新型冠状病毒肺炎重症和/或危重症患者的存活率。
优选的，所述肌酐的剂型为片剂、胶囊、口服液体制剂、乳液和注射液中的一种或多种。
优选的，所述药物的剂型为片剂、胶囊、口服液体制剂、乳液和注射液中的一种或多种。
通过上述技术方案，肌苷可降低自身免疫性疾病、癌症或过敏性肺炎等疾病的炎性因子水平，抑制巨噬细胞、淋巴细胞和中性粒细胞的活化，从而改善肠道和肺损伤。且肌苷能通过细胞因子风暴调控，从而改善重症或危重症COVID-19的存活率。
肌苷能够减轻SARS-COV-2诱导的肺脏组织病理学变化、抑制细胞因子IL-6的分泌。在SARS-CoV-2诱导的细胞因子风暴(CRS)过程中，IL-6是最关键的细胞因子之一，其严重程度与IL-6的升高密切相关，因此，控制IL-6有助于控制细胞因子风暴，肌苷能够抑制SARS-COV-2诱导的IL-6的高表达，从而能够有效控制SARS-CoV-2导致的肺部炎性损伤，进而大幅提升SARS-CoV-2危重症存活率。
综上所述，本发明具有以下有益效果：
1.该肌苷药物能够降低SARS-COV-2诱导的IL-6的高表达，从而能够有效控制SARS-CoV-2导致的肺部炎性损伤，进而大幅提升SARS-CoV-2危重症存活率。
2.该肌苷药物为重症、危重症新冠肺炎患者及其家庭带来了希望，并为治疗新冠肺炎重症、危重症患者提供了新思路。
附图说明
图1是本发明实施例的肌苷能提高新冠致死动物模型存活率的实验 数据统计图；
图2是本发明实施例的肌苷能促进新冠感染动物体重恢复的实验数据统计图；
图3本发明实施例的肌苷能有效控制并恢复新冠感染动物肺部炎性损伤的实验结果示意图；
图4本发明实施例的肌苷能抑制由SARS-CoV-2诱导的IL-6水平的实验结果示意图。
具体实施方式
下面结合附图和实施方式对本发明作进一步的详细说明：
实施例：一种药物在治疗新型冠状病毒肺炎中的应用，药物为肌苷，将肌苷应用于抑制IL-6水平，从而抑制SARS-COV-2；肌苷为片剂、胶囊、口服液体制剂、乳液和注射液中的一种或多。
肌苷能够大幅提升SARS-CoV-2危重症存活率。本实施例的检测结果如下：
A.肌苷能提高新冠致死动物模型存活率，能促进新冠感染动物体重恢复。
如图1至图2所示，肌苷能够提高小鼠的存活率。研究结果表明，感染SARS-COV-2(model组)的Balb/c小鼠在第4至7天因病毒感染导致多器官炎症而死亡，并且体重下降明显。(Inosine组)预防性服用肌苷后，我们观察到Balb/c小鼠的生存期显著延长，小鼠体重下降幅度较小，并且在感染后第8天体重逐渐回升。
B.肌苷能够减轻SARS-COV-2诱导的小鼠肺脏组织病理学变化。
如图3所示，肌苷能够减轻SARS-COV-2诱导的小鼠肺脏组织病理学变化。通过H&E染色观察肌苷对肺脏组织病理学的影响，结果显示，与空白对照组(Vehicle组)相比，感染SARS-COV-2组(model组)可见点、片状出血，出现大量中性粒细胞浸润，和肺间质水肿现象；而口服肌苷组(Inosine组)的肺组织结构完整，肺泡腔清晰，肺泡壁无充血，炎症浸润现象较SARS-COV-2组有明显的改善。
C.肌苷抑制细胞因子IL-6的分泌。
在细胞因子风暴(CRS)发生过程中，IL-6是最关键的细胞因子之一， 其严重程度与IL-6的升高密切相关；在SARS-CoV-2诱导的细胞因子风暴中IL-6亦发挥着重要作用。为了确定肌苷是否能够抑制IL-6的分泌，通过Elisa测定了小鼠血清中细胞因子IL-6的水平。结果表明，肌苷(Inosine组)能够抑制SARS-COV-2诱导的IL-6的高表达，并通过控制IL-6有助于控制细胞因子风暴。
结论：肌苷能通过抑制IL-6水平，有效控制SARS-CoV-2导致的肺部炎性损伤，大幅提升SARS-CoV-2危重症存活率。
在本发明的上述实施例中，该药物能够降低SARS-COV-2诱导的IL-6的高表达，从而能够有效控制SARS-CoV-2导致的肺部炎性损伤，进而大幅提升SARS-CoV-2危重症存活率。该药物为重症、危重症新冠肺炎患者及其家庭带来了希望，并为治疗新冠肺炎重症、危重症患者提供了新思路。
本具体实施例仅仅是对本发明的解释，其并不是对本发明的限制，本领域技术人员在阅读完本说明书后可以根据需要对本实施例做出没有创造性贡献的修改，但只要在本发明的权利要求范围内都受到专利法的保护。

Claims (6)

  1. 肌苷在预防和/或治疗新型冠状病毒肺炎中的应用。
  2. 肌苷在制备预防和/或治疗新型冠状病毒肺炎的药物中的应用。
  3. 根据权利要求1或2所述的应用，其特征在于，所述肌酐通过抑制细胞因子IL-6的分泌和/或减轻SARS-CoV-2导致的肺部炎性损伤来治疗新型冠状病毒肺炎。
  4. 根据权利要求1或2所述的应用，其特征在于，所述治疗新型冠状病毒肺炎包括提高治疗新型冠状病毒肺炎重症和/或危重症患者的存活率。
  5. 根据权利要求1所述的应用，其特征在于，所述肌酐的剂型为片剂、胶囊、口服液体制剂、乳液和注射液中的一种或多种。
  6. 根据权利要求2所述的应用，其特征在于，所述药物的剂型为片剂、胶囊、口服液体制剂、乳液和注射液中的一种或多种。
PCT/CN2022/078715 2021-12-16 2022-03-02 肌苷在制备治疗新型冠状病毒肺炎的药物中的应用 WO2023108905A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/271,296 US20240299436A1 (en) 2021-12-16 2022-03-02 Use of Inosine in Preparing Drug For Treatment of Corona Virus Disease 2019

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111541575.0A CN114099531A (zh) 2021-12-16 2021-12-16 一种药物在治疗新型冠状病毒肺炎中的应用
CN202111541575.0 2021-12-16

Publications (1)

Publication Number Publication Date
WO2023108905A1 true WO2023108905A1 (zh) 2023-06-22

Family

ID=80365117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/078715 WO2023108905A1 (zh) 2021-12-16 2022-03-02 肌苷在制备治疗新型冠状病毒肺炎的药物中的应用

Country Status (3)

Country Link
US (1) US20240299436A1 (zh)
CN (1) CN114099531A (zh)
WO (1) WO2023108905A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114099531A (zh) * 2021-12-16 2022-03-01 中国人民解放军军事科学院军事医学研究院 一种药物在治疗新型冠状病毒肺炎中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021201224A1 (ja) * 2020-04-02 2021-10-07 株式会社スタージェン ミトコンドリア保護剤、ミトコンドリア障害改善剤、またはミトコンドリア機能改善剤
WO2021205437A1 (en) * 2020-04-06 2021-10-14 Vecht Lifshitz Susan Eve Pharmaceutical compositions for treating corona virus disease
EP3906922A1 (en) * 2020-05-07 2021-11-10 4Living Biotech New compositions and methods of treating covid-19 disease
WO2022003531A1 (en) * 2020-07-01 2022-01-06 Iachettini Giampietro Modified adenosine nucleoside for use in the treatment of viral infections
CN114099531A (zh) * 2021-12-16 2022-03-01 中国人民解放军军事科学院军事医学研究院 一种药物在治疗新型冠状病毒肺炎中的应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021201224A1 (ja) * 2020-04-02 2021-10-07 株式会社スタージェン ミトコンドリア保護剤、ミトコンドリア障害改善剤、またはミトコンドリア機能改善剤
WO2021205437A1 (en) * 2020-04-06 2021-10-14 Vecht Lifshitz Susan Eve Pharmaceutical compositions for treating corona virus disease
EP3906922A1 (en) * 2020-05-07 2021-11-10 4Living Biotech New compositions and methods of treating covid-19 disease
WO2022003531A1 (en) * 2020-07-01 2022-01-06 Iachettini Giampietro Modified adenosine nucleoside for use in the treatment of viral infections
CN114099531A (zh) * 2021-12-16 2022-03-01 中国人民解放军军事科学院军事医学研究院 一种药物在治疗新型冠状病毒肺炎中的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERAN JIŘÍ, ŠPAJDEL MARIÁN, SLÍVA JIŘÍ: "Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course", VIRUSES, vol. 13, no. 11, pages 2246, XP093073095, DOI: 10.3390/v13112246 *
FALCONE CARMELA, CARACCIOLO MASSIMO, CORREALE PIERPAOLO, MACHEDA SEBASTIANO, VADALà EUGENIO GIUSEPPE, LA SCALA STEFANO, TESCI: "Can Adenosine Fight COVID-19 Acute Respiratory Distress Syndrome?", JOURNAL OF CLINICAL MEDICINE, vol. 9, no. 9, pages 3045, XP055778252, DOI: 10.3390/jcm9093045 *
JIANG, LEI: "Evaluation on Effect of Inosine for Treating Severe Sepsis in 35 Cases", CHINA PHARMACEUTICALS, vol. 24, no. 12, 20 June 2015 (2015-06-20), XP009547131, ISSN: 1006-4931 *

Also Published As

Publication number Publication date
US20240299436A1 (en) 2024-09-12
CN114099531A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
US10787502B2 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
CN111991401A (zh) 一种化合物在治疗SARS-CoV-2感染中的应用
WO2023108905A1 (zh) 肌苷在制备治疗新型冠状病毒肺炎的药物中的应用
EP3317290A1 (en) Compositions and methods for the treatment of viral infection
Li et al. Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome
Wei et al. Refined polysaccharide from Dendrobium devonianum resists H1N1 influenza viral infection in mice by activating immunity through the TLR4/MyD88/NF-κB pathway
Lu et al. Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis.
WO2022057861A1 (zh) 二萜化合物或其盐在制备防治急性肺损伤的药物中的应用
CN116459295B (zh) 一种肺炎清化方及其应用
Komuro Kampo medicines for infectious diseases
JP2010083871A (ja) 抗アデノウイルス剤を含有する医薬組成物
TW202200196A (zh) 用人α-1抗胰蛋白酶治療病毒感染的方法
CN115089590A (zh) 环戊基三唑嘧啶类药物作为药物成分在肝炎药物中的应用
CN102716128A (zh) 一种治疗哮喘的药用组合物
CN112043718A (zh) 异甘草酸镁在制备治疗结肠炎药物中的应用
Aguero Echeverría COVID19: State of the Art of Antiviral Management
CN112891482B (zh) 一种治疗新型冠状病毒感染的组合物
CN104998250B (zh) 一种恩替卡韦与甘露聚糖肽药物组合物及其制备方法
CN106727652A (zh) 一种用于缓解骨关节炎疼痛的分子中药缓释片及其制备方法
CN117503745A (zh) 脱氧蒜氨酸作为肥大细胞活化抑制剂的应用
CN117462633A (zh) 荆银固表方在治疗流感以及流感继发细菌感染疾病中的应用
WO2022250578A1 (ru) Применение 2-(имидазол-4-ил)-этанамид пентандиовой- 1,5 кислоты для лечения covid-19
Jeyashree et al. INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL SCIENCES
CN105663237B (zh) 中药组合物及其制备方法和应用
CN117838689A (zh) 培菲替尼在制备治疗流感病毒感染的药物中的应用

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 18271296

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22905676

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE